IND Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System: Guidance for Industry and FDA Staff
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 1, 2014
May 16, 2019
11261772-181c-4193-9a2c-ff10ff47b76a
Related Documents
Preclinical Assessment of Investigational Cellular and Gene Therapy Products: Guidance for Industry
Guidance DocumentNovember 1, 2013Center for Biologics Evaluation and Research
BLA for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System: Guidance for Industry
Guidance DocumentMarch 1, 2014Center for Biologics Evaluation and Research
Blood Establishment Computer System Validation in the User's Facility: Guidance for Industry
Guidance DocumentApril 1, 2013Center for Biologics Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.